President Donald Trump announced that his administration reached an agreement with pharmaceutical company AstraZeneca to lower prices on select medications for U.S. patients.
The deal represents the second partnership between the administration and a major drug manufacturer to reduce prescription costs.
Under the agreement, AstraZeneca will reduce prices on specific drugs available to Medicaid beneficiaries, aiming to ease the financial strain on patients who rely on essential medications.
AstraZeneca will also join the “TrumpRx” website, which provides information on discounted drug options. The platform is designed to help consumers find affordable prescriptions more easily and minimize overall healthcare expenses.
This latest agreement follows a similar arrangement announced earlier with another major pharmaceutical company. The administration continues to pursue voluntary industry partnerships as a way to bring down drug prices without waiting for new legislation.
AstraZeneca executives expressed support for the effort, highlighting the company’s commitment to expanding access to life-saving treatments. Details on which medications are included and the scale of discounts are expected to be released in the coming weeks.
Healthcare policy experts note that while these agreements may offer short-term relief, long-term solutions will require more comprehensive reforms. The administration’s continued collaboration with the pharmaceutical sector marks a strategic step toward addressing the high cost of prescription drugs in the United States.
